公开(公告)号：US20170226121A1

公开(公告)日：2017-08-10

申请号：US15287593

申请日：2016-10-06

Applicant: Indiana University Research and Technology Corporation ,  Scripps Research Institute, A Not-for-Profit Public Benefit Corporation of California

Inventor： Adam Zlotnick ,  M.G. Finn

IPC: C07D493/10 ,  C07D417/04 ,  C07D401/14 ,  C07D401/12 ,  C07D491/113 ,  C07D471/04 ,  C07D239/22 ,  C07D401/04 ,  C07D239/20

CPC classification number: C07D493/10 ,  A61K31/496 ,  C07D239/20 ,  C07D239/22 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/04 ,  C07D471/04 ,  C07D491/10 ,  C07D491/113

Abstract: In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described.

公开(公告)号：US20150292045A1

公开(公告)日：2015-10-15

申请号：US14441621

申请日：2013-11-08

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Massimo Levrero ,  Adam Zlotnick

IPC: C12Q1/70 ,  A61K31/4453 ,  A61K31/506

CPC classification number: C12Q1/706 ,  A61K31/4453 ,  A61K31/506 ,  C07D239/28 ,  C07D239/40 ,  C07D401/04 ,  C07D401/14 ,  C07D417/04 ,  C07D491/10 ,  C07D493/10 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV).

Abstract translation: 本文描述了鉴定用于治疗乙型肝炎病毒（HBV）感染的化合物的方法。

公开(公告)号：US20140148381A1

公开(公告)日：2014-05-29

申请号：US14232377

申请日：2012-07-13

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Adam Zlotnick ,  Daniel Loeb

IPC: A61K38/16

CPC classification number: A61K38/162 ,  A01K67/027 ,  A01K2207/05 ,  A01K2267/0337 ,  A61K38/00 ,  C07K14/005 ,  C12N2730/10122 ,  C12N2730/10133 ,  C12N2740/16222 ,  C12N2799/025 ,  G01N33/56983

Abstract: This disclosure provides a novel strategy to cope with chronic virus infection by introducing a dominant negative viral structural protein to disturb effective virion production. The dominant negative structural protein mimics antiviral drugs through structural and biochemical interactions during virus assembly. An effective gene therapy model for chronic viral infected diseases is proposed in this disclosure, as represented by HBV Cpdominant 1 to clear viral infection.

Abstract translation: 本公开提供了通过引入显性阴性病毒结构蛋白来干扰有效的病毒粒子产生来应对慢性病毒感染的新策略。 显性阴性结构蛋白在病毒组装过程中通过结构和生化相互作用模拟抗病毒药物。 在本公开中提出了用于慢性病毒感染疾病的有效的基因治疗模型，由HBV Cpdominant 1表示以清除病毒感染。